Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study

• Status: Withdrawn
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the feasibility of prospectively enrolling and randomizing patients with aneurysmal subarachnoid hemorrhage (aSAH) to receive levetiracetam or not to receive levetiracetam, and documenting in-hospital and follow-up clinical variables.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• ≥ 18 years of age

• ≤ 75 years of age

• Newly diagnosed aneurysmal subarachnoid hemorrhage

Exclusion Criteria:

• One or more antiepileptic medication is taken as a pre-admission medication

• Seizure occurrence in the field or in the emergency department, or anytime before consent could be obtained

• Inability to obtain informed consent from the patient, or from the patient's appropriate surrogate